Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease: A Systematic Review and Meta-analysis
The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: The association of nonmotor features and Parkinson disease (PD) is increasingly recognized. Evidence suggests that inflammation may play a role in PD pathologic features and symptoms. OBJECTIVE: To quantitatively summarize the peripheral inflammatory cytokine data available for patients with PD. DATA SOURCE: A systematic search of peer-reviewed English-language articles from PubMed, PsycINFO, and the Cochrane Library without year limitation was performed from December 7, 2015, to March 23, 2016. The search terms included inflammation or cytokine or chemokine or tumor necrosis factor or interleukin or interferon or C-reactive protein AND Parkinson disease. STUDY SELECTION: Studies were included if they provided data on peripheral blood cytokine concentrations in patients with PD and a healthy control group. Studies were excluded if they contained in vitro analysis of stimulated or unstimulated levels of cytokines, samples that overlapped with other studies, patients not diagnosed with PD at blood sampling, or if the cytokine analyzed was assessed in fewer than 3 studies. DATA EXTRACTION AND SYNTHESIS: Data were extracted from the 25 included studies encompassing 1547 unique patients with PD and 1107 unique controls by 2 independent investigators. Data were pooled using a random-effects model with the Comprehensive Meta-analysis software. Effect sizes were generated as standardized mean differences of cytokine concentrations between patients with PD and healthy controls and converted to the Hedges g statistic. MAIN OUTCOMES AND MEASURES: Blood cytokine concentrations in patients with PD compared with controls. Aberrations in peripheral cytokine levels were hypothesized to be related to PD. RESULTS: Among the 2654 study participants, concentrations of interleukin 6 (IL-6) (Hedges g, 0.325; 95% CI, 0.007-0.643; P = .045) in 13 studies, tumor necrosis factor (Hedges g, 0.354; 95% CI, 0.144-0.563; P = .001) in 9 studies, IL-1β (Hedges g, 0.382; 95% CI, 0.142-0.621; P = .002) in 6 studies, C-reactive protein (Hedges g, 0.323; 95% CI, 0.052-0.593; P = .02) in 6 studies, IL-10 (Hedges g, 0.329; 95% CI, 0.051-0.607; P = .02) in 5 studies, RANTES (regulated on activation, normal T-expressed, and presumably secreted) (Hedges g, 0.605; 95% CI, 0.111-1.099; P = .02) in 5 studies, and IL-2 (Hedges g, 0.789; 95% CI, 0.105-1.472; P = .02) in 3 studies were significantly higher in patients with PD compared with healthy controls. No differences were found between patients with PD and healthy controls for concentrations of interferon-γ (Hedges g, 0.745; 95% CI, -0.192 to 1.682; P = .12) in 5 studies, IL-4 (Hedges g, 0.031; 95% CI, -0.191 to 0.253; P = .79) in 3 studies, and IL-8 (Hedges g, 0.072; 95% CI, -0.136 to 0.279; P = .50) in 3 studies. CONCLUSIONS AND RELEVANCE: The findings of the meta-analysis demonstrated higher peripheral concentrations of IL-6, tumor necrosis factor, IL-1β, IL-2, IL-10, C-reactive protein, and RANTES in patients with PD, strengthening the clinical evidence that PD is accompanied by an inflammatory response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Statistical Methods for Meta-Analysis
Wasserman, S., Hedges, L. V., & Olkin, I. (1988) · Journal of Educational Statistics · doi:10.2307/1164953 · Cited by 10,326
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720 · cited 1×
“The following exclusion criteria were applied: (1) in vitro studies that reported stimulated or unstimulated levels of cytokines; (2) samples overlapped with other studies; (3) patients were not diagnosed with PD at the time of blood sampling; and (4) the cytokine analyzed was assessed in fewer than 3 studies.”
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Quantitative Synthesis in Systematic Reviews
Lau, J., Ioannidis, J. P. A., & Schmid, C. H. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-9-199711010-00008 · Cited by 2,517
Goetz, C. G., Poewe, W., Rascol, O., Sampaio, C., Stebbins, G. T., Counsell, C., Giladi, N., Holloway, R. G., Moore, C. G., Wenning, G. K., et al. (2004) · Movement Disorders · doi:10.1002/mds.20213 · Cited by 2,347
Cited by
The pathogenesis of Parkinson's disease
Morris, H. R., Spillantini, M. G., Sue, C. M., & Williams-Gray, C. H. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01478-2 · Cited by 1,019
Aho, V. T. E., Houser, M. C., Pereira, P. A. B., Chang, J., Rudi, K., Paulin, L., Hertzberg, V., Auvinen, P., Tansey, M. G., & Scheperjans, F. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00427-6 · Cited by 435
Insulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 328
CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease
Williams, G. P., Schonhoff, A. M., Jurkuvenaite, A., Gallups, N. J., Standaert, D. G., & Harms, A. S. (2021) · Brain · doi:10.1093/brain/awab103 · Cited by 306
Chen, X., Hu, Y., Cao, Z., Liu, Q., & Cheng, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02122 · Cited by 288
Self-citationOxidative Stress in Parkinson's Disease: A Systematic Review and Meta-Analysis
Wei, Z., Li, X., Li, X., Liu, Q., & Cheng, Y. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00236 · Cited by 281
Self-citationMatsumoto, J., Stewart, T., Sheng, L., Li, N., Bullock, K., Song, N., Shi, M., Banks, W. A., & Zhang, J. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0470-4 · Cited by 279
The role of Toll-like receptors and neuroinflammation in Parkinson’s disease
Heidari, A., Yazdanpanah, N., & Rezaei, N. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02496-w · Cited by 275
Periphery and brain, innate and adaptive immunity in Parkinson’s disease
Harms, A. S., Ferreira, S. A., & Romero-Ramos, M. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02268-5 · Cited by 272
Pellegrini, C., Antonioli, L., Colucci, R., Blandizzi, C., & Fornai, M. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1856-5 · Cited by 270
“Taken together, these findings allow to hypothesize that, in PD, changes in gut microbiota composition, mainly the loss of SCFAproducing bacteria, along with an increase in intestinal permeability, could shape enteric inflammatory/neurogenic responses and promote α-syn accumulation in myenteric neurons that, besides t…”
BackgroundBiomarker of Neuroinflammation in Parkinson’s Disease
Liu, T.-W., Chen, C.-M., & Chang, K.-H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084148 · Cited by 259
Fan, Z., Pan, Y.-T., Zhang, Z.-Y., Yang, H., Yu, S.-Y., Zheng, Y., Ma, J.-H., & Wang, X.-M. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1670-6 · Cited by 228
Huang, B., Chau, S. W. H., Liu, Y., Chan, J. W. Y., Wang, J., Ma, S. L., Zhang, J., Chan, P. K. S., Yeoh, Y. K., Chen, Z., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38248-4 · Cited by 187
Hu, Y., Cao, C., Qin, X.-Y., Yu, Y., Yuan, J., Zhao, Y., & Cheng, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-09097-1 · Cited by 183
Self-citationPellegrini, C., Antonioli, L., Calderone, V., Colucci, R., Fornai, M., & Blandizzi, C. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101806 · Cited by 174
Hertel, J., Harms, A. C., Heinken, A., Baldini, F., Thinnes, C. C., Glaab, E., Vasco, D. A., Pietzner, M., Stewart, I. D., Wareham, N. J., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.035 · Cited by 162
Li, Y., Peng, Y., Shen, Y., Zhang, Y., Liu, L., & Yang, X. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2076064 · Cited by 156
“The inflammatory cytokines (such as TNF-α, IL-1β, IL-2, IL-6, IL-10, interferon-γ [IFN-γ], C-reactive protein [CRP] and C-C chemokine ligand 5 [CCL5]) were the most common dysregulated factors in the peripheral blood of PD patients (Qin et al. 2016).”
BackgroundThe Link between Gut Dysbiosis and Neuroinflammation in Parkinson’s Disease
Baizabal-Carvallo, J. F., & Alonso-Juarez, M. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.02.030 · Cited by 130
Iba, M., Kim, C., Sallin, M., Kwon, S., Verma, A., Overk, C., Rissman, R. A., Sen, R., Sen, J. M., & Masliah, E. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01888-0 · Cited by 120
“In support of this possibility, we found increased levels of TNF α and have previously shown increased IL-1 β and IL-6 mRNA expression in α -syn tg mice, which are known to correlate with astrogliosis and inflammation in PD/DLB mouse models [48, 90] and patients [91].”
RetractedZhang, Y., Che, M., Yuan, J., Yu, Y., Cao, C., Qin, X.-Y., & Cheng, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.21060 · Cited by 98
Self-citationRoser, A.-E., Tönges, L., & Lingor, P. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00094 · Cited by 77
Liu, S.-Y., Qiao, H.-W., Song, T.-B., Liu, X.-L., Yao, Y.-X., Zhao, C.-S., Barret, O., Xu, S.-L., Cai, Y.-N., Tamagnan, G. D., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02574-z · Cited by 62
“We also found an elevation of frequencies of Th17 cells and serum level of proinflammatory IL17A and significant increase in serum level of antiinflammatory IL-10, in agreement with the findings of increased serum levels of IL-6, TNF-α, IL-1β, IL-2, and IL-10 in PD patients from a meta-analysis of 25 studies and 2654…”
BackgroundResultRifampicin Inhibits Rotenone-Induced Microglial Inflammation via Enhancement of Autophagy
Liang, Y., Zhou, T., Chen, Y., Lin, D., Jing, X., Peng, S., Zheng, D., Zeng, Z., Lei, M., Wu, X., et al. (2017) · NeuroToxicology · doi:10.1016/j.neuro.2017.09.015 · Cited by 55
“A great wealth of epidemiological, clinical, and experimental evidence has implicated that inflammatory processes contribute to the progressive degeneration of the dopaminergic nigrostriatal pathway and the pathophysiology of PD (He et al., 2017; Qin et al., 2016).”
BackgroundMulticenter Alzheimer's and Parkinson's disease immune biomarker verification study
Brosseron, F., Kolbe, C., Santarelli, F., Carvalho, S., Antonell, A., Castro‐Gomez, S., Tacik, P., Namasivayam, A. A., Mangone, G., Schneider, R., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.07.018 · Cited by 47
Genetic Defects and Pro-inflammatory Cytokines in Parkinson's Disease
Magnusen, A. F., Hatton, S. L., Rani, R., & Pandey, M. K. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.636139 · Cited by 47
Farrerol attenuates MPP+‐induced inflammatory response by TLR4 signaling in a microglia cell line
Cui, B., Guo, X., You, Y., & Fu, R. (2019) · Phytotherapy Research · doi:10.1002/ptr.6307 · Cited by 35
Evidence for immune system alterations in peripheral biological fluids in Parkinson’s disease
Bartl, M., Xylaki, M., Bähr, M., Weber, S., Trenkwalder, C., & Mollenhauer, B. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105744 · Cited by 33
Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?
Gundersen, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.580311 · Cited by 33
Age-Related Adaptive Immune Changes in Parkinson’s Disease
Kouli, A., & Williams-Gray, C. H. (2022) · Journal of Parkinson's Disease · doi:10.3233/jpd-223228 · Cited by 20
Research Progress on the Relationship between Parkinson's Disease and REM Sleep Behavior Disorder
Zhou, Y., Liu, X., & Xu, B. (2024) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2309166 · Cited by 13
Woo, K. A., Jang, Y., Kim, H.-J., & Park, P. J. (2026) · Brain · doi:10.1093/brain/awag130 · Cited by 3
Metadata
- Authors
- Qin, X.-Y., Zhang, S.-P., Cao, C., Loh, Y. P., & Cheng, Y.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2016-11-01
- Volume
- 73
- Issue
- 11
- Pages
- 1316
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2525903933
- Cited by
- 554
- References
- 72
- FWCI
- 18.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.